» Articles » PMID: 26211420

Animal Models of Barrett's Esophagus and Esophageal Adenocarcinoma-Past, Present, and Future

Overview
Journal Clin Transl Sci
Date 2015 Jul 28
PMID 26211420
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Esophageal adenocarcinoma is the fastest rising cancer in the United States. It develops from long-standing gastroesophageal reflux disease which affects >20% of the general population. It carries a very poor prognosis with 5-year survival <20%. The disease is known to sequentially progress from reflux esophagitis to a metaplastic precursor, Barrett's esophagus and then onto dysplasia and esophageal adenocarcinoma. However, only few patients with reflux develop Barrett's esophagus and only a minority of these turn malignant. The reason for this heterogeneity in clinical progression is unknown. To improve patient management, molecular changes which facilitate disease progression must be identified. Animal models can provide a comprehensive functional and anatomic platform for such a study. Rats and mice have been the most widely studied but disease homology with humans has been questioned. No animal model naturally simulates the inflammation to adenocarcinoma progression as in humans, with all models requiring surgical bypass or destruction of existing antireflux mechanisms. Valuable properties of individual models could be utilized to holistically evaluate disease progression. In this review paper, we critically examined the current animal models of Barrett's esophagus, their differences and homologies with human disease and how they have shaped our current understanding of Barrett's carcinogenesis.

Citing Articles

Esophageal adenocarcinoma models: a closer look.

Bhat N, Al-Mathkour M, Maacha S, Lu H, El-Rifai W, Ballout F Front Mol Biosci. 2024; 11:1440670.

PMID: 39600303 PMC: 11589788. DOI: 10.3389/fmolb.2024.1440670.


Defining precancer: a grand challenge for the cancer community.

Faupel-Badger J, Kohaar I, Bahl M, Chan A, Campbell J, Ding L Nat Rev Cancer. 2024; 24(11):792-809.

PMID: 39354069 DOI: 10.1038/s41568-024-00744-0.


Modelling esophageal adenocarcinoma and Barrett's esophagus with patient-derived organoids.

Milne J, Mustafa E, Clemons N Front Mol Biosci. 2024; 11:1382070.

PMID: 38721276 PMC: 11076827. DOI: 10.3389/fmolb.2024.1382070.


Adenocarcinoma of the distal esophagus and esophageal-proventricular junction in a yellow-naped parrot.

Hines E, Jones S, Hoppes S, Stranahan L J Vet Diagn Invest. 2024; 36(4):586-589.

PMID: 38653775 PMC: 11185118. DOI: 10.1177/10406387241247282.


Causal analysis of gastroesophageal reflux disease and esophageal cancer.

Wang S, Li Z, Zhou Z, Kang M Medicine (Baltimore). 2024; 103(11):e37433.

PMID: 38489737 PMC: 10939529. DOI: 10.1097/MD.0000000000037433.


References
1.
Christie K, Thomson C, Hopwood D . A comparison of membrane enzymes of human and pig oesophagus; the pig oesophagus is a good model for studies of the gullet in man. Histochem J. 1995; 27(3):231-9. View

2.
Rubio C, Dick Jr E, Orrego A, Hubbard G . The frequency of glassy cells in Barrett's mucosa: a study in Baboons. In Vivo. 2009; 23(6):925-7. PMC: 3420813. View

3.
Crawford S, Stellmach V, Murphy-Ullrich J, Ribeiro S, Lawler J, Hynes R . Thrombospondin-1 is a major activator of TGF-beta1 in vivo. Cell. 1998; 93(7):1159-70. DOI: 10.1016/s0092-8674(00)81460-9. View

4.
Kambhampati S, Rajewski R, Tanol M, Haque I, Das A, Banerjee S . A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. Mol Cancer Ther. 2013; 12(3):255-63. PMC: 4729448. DOI: 10.1158/1535-7163.MCT-12-0777. View

5.
Kosovec J, Zaidi A, Komatsu Y, Kasi P, Cothron K, Thompson D . Establishing magnetic resonance imaging as an accurate and reliable tool to diagnose and monitor esophageal cancer in a rat model. PLoS One. 2014; 9(4):e93694. PMC: 3976303. DOI: 10.1371/journal.pone.0093694. View